Neuroprotective effect of Portulaca oleracea extracts against 6-hydroxydopamine-induced lesion of dopaminergic neurons.

The Portulaca oleracea L. (Portulacaceae) is a cosmopolitan species with a wide range of biological activities, including antioxidant and neuroprotective actions. We investigated the effects of P. oleracea extracts in a 6-hydroxydopamine rat model of Parkinson's disease, a debilitating disorder without effective treatments. Chemical profiles of aqueous and ethanolic extracts of whole plant were analyzed by thin layer chromatography and the antioxidant activity was assessed by 2,2-diphenyl-1-picrilhidrazila method. Male Wistar rats received intrastriatal 6-hydroxydopamine and were treated with vehicle or extracts (oral, 200 and 400 mg/kg) daily for two weeks. The behavioral open field test was conducted at days 1 and 15. Immunohistochemical analysis was performed 4 weeks after surgery to quantify tyrosine-hydroxylase cell counts in the substantia nigra pars compacta. Extracts presented antioxidant activity in concentrations above 300 µg/kg. The chromatographic analysis revealed the presence of Levodopa, alkaloids, flavonoids, saponins, tannins, terpenoids and polysaccharides. Both extracts improved motor recovery 15 days after lesion and protected from tyrosine-hydroxylase cell loss after 4 weeks, but these effects were more evident for the aqueous extract. Because the dopamine precursor is present, in addition to antioxidant compounds and neuroprotective effects, P. oleracea can be considered as potential strategy for treating Parkinson's disease.

Evaluation of the neurotoxic/neuroprotective role of organoselenides using differentiated human neuroblastoma SH-SY5Y cell line challenged with 6-hydroxydopamine.

It is well established that oxidative stress plays a major role in several neurodegenerative conditions, like Parkinson disease (PD). Hence, there is an enormous effort for the development of new antioxidants compounds with therapeutic potential for the management of PD, such as synthetic organoselenides molecules. In this study, we selected between nine different synthetic organoselenides the most eligible ones for further neuroprotection assays, using the differentiated human neuroblastoma SH-SY5Y cell line as in vitro model. Neuronal differentiation of exponentially growing human neuroblastoma SH-SY5Y cells was triggered by cultivating cells with DMEM/F12 medium with 1% of fetal bovine serum (FBS) with the combination of 10 µM retinoic acid for 7 days. Differentiated cells were further incubated with different concentrations of nine organoselenides (0.1, 0.3, 3, 10, and 30 µM) for 24 h and cell viability, neurites densities and the immunocontent of neuronal markers were evaluated. Peroxyl radical scavenging potential of each compound was determined with TRAP assay. Three organoselenides tested presented low cytotoxicity and high antioxidant properties. Pre-treatment of cells with those compounds for 24 h lead to a significantly neuroprotection against 6-hydroxydopamine (6-OHDA) toxicity, which were directly related to their antioxidant properties. Neuroprotective activity of all three organoselenides was compared to diphenyl diselenide (PhSe)2, the simplest of the diaryl diselenides tested. Our results demonstrate that differentiated human SH-SY5Y cells are suitable cellular model to evaluate neuroprotective/neurotoxic role of compounds, and support further evaluation of selected organoselenium molecules as potential pharmacological and therapeutic drugs in the treatment of PD.

Protective effects of N-acetylserotonin against 6-hydroxydopamine-induced neurotoxicity.

The present work studied in vivo neuroprotective effects of n-acetylserotonin (NAS), the immediate precursor of melatonin, on the dopaminergic system, in rats lesioned with the unilateral intrastriatal injection of the neurotoxin 6-hydroxydopamine (6-OHDA). Two weeks after the lesion, the dopamine receptor agonist, apomorphine, produced rotational asymmetry, and the NAS treatment significantly reduced the motor deficit following the apomorphine challenge. The apomorphine-induced rotational behavior was blocked by 84, 86 and 53% after NAS, at doses of 2, 5 and 10 mg/kg, i.p., respectively. The injection of 6-OHDA significantly decreased DA, DOPAC and HVA levels in the rat striatum. In contrast, the NAS (2, 5 and 10 mg/kg, i.p., daily for 7 days) treatment partially reversed the decreases caused by 6-OHDA, and the neurotransmitter levels were brought to approximately 50% of that observed in the contralateral sides. NAS was more efficient at the smaller doses. NAS (5 mg/kg) produced an up-regulation of D1 (37%) and D2 (37%) receptors associated with a decrease in Kd values.

Effect of the hydroalcoholic extract of rauwolfia ligustrina on smooth and cardiac muscles in-vitro.

The actions of the hydroalcoholic extract (HE) of Rauwolfia ligustrina (the whole plant) on agonist-induced contractions were analysed in the rat uterus and guinea-pig ileum and trachea, and also in rat atrium contracting spontaneously in-vitro. The HE (100-400 micrograms mL-1) caused concentration-dependent rightward shifts of the concentration-response curves and reduced the maximal contraction induced by oxytocin, bradykinin, angiotensin II, prostaglandin F2 alpha and acetylcholine in the rat uterus. The calculated mean IC50 values were: 300, 147, 158, 197 and 105 micrograms mL-1, respectively. In the guinea-pig ileum the HE also caused graded displacement to the right of the concentration-response curves for bradykinin, histamine and carbachol, associated with pronounced inhibition of the agonist-induced maximal contractions. The calculated mean IC50 values were 165, 134 and 241 micrograms mL-1, respectively. The HE (100-3000 micrograms mL-1) caused graded relaxation (IC50 of 271 micrograms mL-1) of strips of guinea-pig trachea precontracted with carbachol (0.2 microM). This effect was not influenced by propranolol (1 microM), 3-isobutyl-1-methylxanthine (1 microM) or methylene blue (10 microM), but was significantly potentiated (1.5-to 3-fold) by indomethacin (3 microM) and forskolin (1 nM). In addition, NG-monomethyl-L-arginine (L-NMMA, 100 nM) significantly reduced the HE-induced maximal relaxation, while indomethacin (3 microM) potentiated the HE response. Finally, the HE caused a concentration-dependent and long-lasting inotropic effect in the rat right atrium, contracting spontaneously with a mean EC50 value of 409 micrograms mL-1. It is suggested that the effects of the HE of R. ligustrina on smooth and cardiac muscles "in-vitro' may result from its ability to interact, at least partially, with the cAMP pathway.

Propiedades antiadrenérgicas alfa de la espiroxatrina, un ligando de los receptores serotonérgicos 5-HT1A / Antiadrenergic properties of spiroxatrine

La espiroxatrina, un ligando 5-HT1A, tiene muy baja afinidad por los sitios de unión Ó1-adrenérgicos y una afinidad relativamente alta por los sitios Ó2. No obstante, estudios funcionales recientes indican que la espiroxatrina es un potente antagonista de los receptores adrenérgicos a1 que median la contracción de la aorta de rata in vitro. Tomando en consideración las notables diferencias en la interacción de los fármacos con los receptores adrenérgicos Ó presentes en los diferentes modelos experimentales, el presente estudio fue diseñado para analizar las propiedades antagonistas Ó-adrenérgicas de la espiroxatrina en la rata descerebrada y desmedulada montada para el registro de la presión arterial. La norepinefrina y los agonistas adrenérgicos Ó1 y Ó2 metoxamina y clonidina, respectivamente, produjeron incrementos de la presión arterial en forma dependiente de la dosis. La espiroxitrina (1 mg/kg, i.v.) produjo un desplazamiento significativo de las curvas dosis-respuesta a los tres agonistas. La magnitud de dicho desplazamiento fue similar en los tres casos. Los resultados presentes sugieren que, aunque la espiroxatrina presenta propiedades antiadrenérgicas Ó1 y Ó2 en el modelo in vivo utilizado en este estudio, su potencia antagonista no parece corresponder con la encontrada en la aorta de rata. La posible participación de subtipo del receptor adrenérgico Ó1 es discutida